» Articles » PMID: 11402224

An Investigation into the Pathogenesis of Vulvo-vaginal Candidosis

Overview
Date 2001 Jun 13
PMID 11402224
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To monitor yeasts isolated from women during and between episodes of recurrent vulvo-vaginal candidosis (VVC) to determine whether vaginal relapse or re-infection occurred.

Methods: Women presenting at the genitourinary medicine clinic with signs and symptoms of VVC were recruited to the study (n = 121). A vaginal washing, high vaginal swab (HVS) and rectal swab were taken and the women treated with a single 500 mg clotrimazole pessary. Women were asked to re-attend after 1, 4, and 12 weeks, or when the VVC recurred, when vaginal washings and HVS were repeated. Candida isolates recovered were strain typed using the Ca3 probe and their similarity assessed. Antifungal susceptibility to fluconazole and clotrimazole were determined.

Results: Of the women recruited, 47 completed the study, either returning for four visits or suffering a recurrence during the study period. Of the 22 women who experienced recurrence, the same strain was responsible for the initial and recurrent episode in 17 women. For the remaining five women, four had strain replacement and one had a change of species. None of the isolates recovered from the women demonstrated resistance to either clotrimazole or fluconazole.

Conclusions: Our findings support the theory of vaginal relapse and thus may support the use of more prolonged courses of antifungal therapy initially to increase the chances of eradication of the yeast.

Citing Articles

Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis.

Garvey E, Hoekstra W, Schotzinger R, Sobel J, Lilly E, Fidel Jr P Antimicrob Agents Chemother. 2015; 59(9):5567-73.

PMID: 26124165 PMC: 4538529. DOI: 10.1128/AAC.00185-15.


Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China.

Ge S, Wan Z, Li J, Xu J, Li R, Bai F Antimicrob Agents Chemother. 2010; 54(8):3126-31.

PMID: 20516286 PMC: 2916359. DOI: 10.1128/AAC.00118-10.


Efficient diagnosis of vulvovaginal candidiasis by use of a new rapid immunochromatography test.

Marot-Leblond A, Nail-Billaud S, Pilon F, Beucher B, Poulain D, Robert R J Clin Microbiol. 2009; 47(12):3821-5.

PMID: 19794036 PMC: 2786628. DOI: 10.1128/JCM.01168-09.


Vulvovaginal candidiasis.

White D, Vanthuyne A Sex Transm Infect. 2006; 82 Suppl 4:iv28-30.

PMID: 17151050 PMC: 2563903. DOI: 10.1136/sti.2006.023168.


Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.

Richter S, Galask R, Messer S, Hollis R, Diekema D, Pfaller M J Clin Microbiol. 2005; 43(5):2155-62.

PMID: 15872235 PMC: 1153777. DOI: 10.1128/JCM.43.5.2155-2162.2005.


References
1.
WALKER P, Reynolds M, Ashbee H, Brown C, EVANS E . Vaginal yeasts in the era of "over the counter" antifungals. Sex Transm Infect. 2001; 76(6):437-8. PMC: 1744236. DOI: 10.1136/sti.76.6.437. View

2.
TASCHDJIAN C, BURCHALL J, Kozinn P . Rapid identification of Candida albicans by filamentation on serum and serum substitutes. AMA J Dis Child. 1960; 99:212-5. DOI: 10.1001/archpedi.1960.02070030214011. View

3.
Milne J, Warnock D . Effect of simultaneous oral and vaginal treatment on the rate of cure and relapse in vaginal candidosis. Br J Vener Dis. 1979; 55(5):362-5. PMC: 1045682. DOI: 10.1136/sti.55.5.362. View

4.
Odds F . Genital candidosis. Clin Exp Dermatol. 1982; 7(4):345-54. DOI: 10.1111/j.1365-2230.1982.tb02441.x. View

5.
Buch A, Skytte Christensen E . Treatment of vaginal candidosis with natamycin and effect of treating the partner at the same time. Acta Obstet Gynecol Scand. 1982; 61(5):393-6. DOI: 10.3109/00016348209156578. View